Intestine and Lower Gastrointestinal Tract · 16 February 2024

Transanal Total Mesorectal Excision (TaTME) Shows High Local Recurrence-Free Survival in Rectal Cancer Patients

Researchers analyzed local recurrence and disease-free survival in patients treated with transanal total mesorectal excision (TaTME) for rectal cancer. The study included 279 patients treated at a high-volume tertiary center in Vancouver, Canada. The results showed that the local recurrence rate was 4.7%, and the estimated 2-year local recurrence-free survival was 95.0% with 94.5% at 5 years. These findings support the oncologic safety of TaTME and its acceptable outcomes.

Journal Article by Hershorn O, Ghuman A (…) Brown CJ et 3 al. in Dis Colon Rectum

read the whole article in Dis Colon Rectum

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

More in Intestine and Lower Gastrointestinal Tract

The latest stitches

Lancet4 Nov 2026

Colorectal cancer: shorter chemo, fewer side effects

A Japanese randomized trial found that a 14-day schedule of trifluridine-tipiracil plus bevacizumab keeps patients with metastatic colorectal cancer alive as long as the standard 28-day schedule, with far less toxicity.

Br J Surg4 Nov 2026

Robot matches laparoscopy for rectal cancer survival

Five years after surgery for low rectal cancer, patients operated on robotically did as well as those operated on laparoscopically, according to a randomized trial from three Korean centres.

Ann Surg Oncol2 Nov 2026

Smoking linked to weaker rectal cancer response

Patients smoking at diagnosis were less likely to have a favorable response to treatment before rectal cancer surgery; former smokers were not.

All papers in Intestine and Lower Gastrointestinal Tract →